Immunome to Present at Upcoming Investor Conferences
Business Wire•18/11/2026•07:30 ET
0
Key Highlights
- ➤Immunome (IMNM) management to present at Evercore Healthcare Conference December 1, 2026
- ➤Immunome (IMNM) management to present at Piper Sandler Healthcare Conference December 2, 2026
- ➤Varegacestat NDA accepted by U.S. FDA; MAA validated by EMA
- ➤Immunome pipeline includes four clinical-stage or IND-cleared oncology therapies
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced that members of the company’s management team will present at the following investor conferences:
Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.immunome.com . Replay webcasts will be available for approximately 30 days following the live presentations.
Get started
Create a free account to read the full story.
